Every Form 4 that Aptevo Therapeutics Inc (APVO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APVO filings page.
Aptevo Therapeutics Inc. director Zsolt Harsanyi reported a derivative exercise involving restricted stock units. On August 6, 2026, 400 RSUs were converted on a one-for-one basis into 400 shares of common stock, with no per-share exercise price reported. The RSU position was reduced to 0, and direct ownership of common stock increased to 400 shares. The RSUs originated from a grant made on August 6, 2025, which vested on the first anniversary of the grant date.
Aptevo Therapeutics Inc. reported that President and CEO Jeffrey G. Lamothe exercised 961 Restricted Stock Units on August 6, 2026. The RSUs converted on a one-for-one basis into 961 shares of common stock, which he now holds directly. The derivative RSU position was reduced to zero in this filing.
Aptevo Therapeutics Inc. reported that SVP & CFO Daphne Taylor exercised 638 Restricted Stock Units on August 6, 2026. The RSUs converted into 638 shares of common stock on a one-for-one basis. These RSUs originated from an August 6, 2025 grant of 11,500 RSUs (638 post-split) that vested on the first anniversary of the grant date.
Aptevo Therapeutics Inc. reported that officer SoYoung Kwon (SVP, GC, BD & Corp Affairs) exercised 638 Restricted Stock Units into 638 shares of common stock on August 6, 2026. The RSUs converted to common stock on a one-for-one basis, leaving 0 RSUs from this grant and resulting in 638 common shares held directly.
Aptevo Therapeutics Inc. officer Dirk Huebner (SVP, CMO) reported the vesting and settlement of 638 Restricted Stock Units (RSUs) into 638 shares of common stock on August 6, 2026. The RSUs, originally granted on August 6, 2025, converted to common stock on a one-for-one basis. In a related transaction, 156 shares of common stock were withheld by the issuer at $4.07 per share to satisfy tax withholding obligations on the RSU vesting.
Aptevo Therapeutics Inc. director Grant Grady III exercised 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. Following the transaction, Grady directly holds 1,150 shares of Aptevo common stock, while the corresponding RSU position was reduced to zero.
Aptevo Therapeutics Inc. reported that Executive Chair Marvin L. White exercised and settled restricted stock units into common stock in July and August 2026. On August 6, 2026, 1,666 RSUs granted on August 6, 2025 converted into common shares, with 406 shares withheld at $4.07 per share to satisfy tax withholding obligations. On July 17, 2026, 1 RSU from a July 17, 2024 grant vested and converted into one common share.
Aptevo Therapeutics Inc. director Daniel Abdun-Nabi reported an exercise of equity awards. On August 6, 2026, 400 Restricted Stock Units converted into 400 shares of Common Stock on a one-for-one basis. The RSU position was reduced by 400 units to zero, and direct ownership of common stock increased to 400 shares following the transaction.
Aptevo Therapeutics Inc. director Barbara Lopez Kunz reported the vesting and conversion of 400 Restricted Stock Units (RSUs) into 400 shares of common stock on August 6, 2026. The RSUs convert into common stock on a one-for-one basis. These 400 RSUs were part of a grant of 7,200 RSUs (400 post-split) awarded on August 6, 2025, which vested on the first anniversary of the grant date.
Aptevo Therapeutics Inc. director John Niederhuber reported the vesting and conversion of 400 Restricted Stock Units into 400 shares of common stock on August 6, 2026. The RSUs converted on a one-for-one basis into common stock. The related footnote states that on August 6, 2025, he was granted 7,200 (400 post-split) RSUs that vest on the first anniversary of the grant date.
Aptevo Therapeutics (APVO) director reported an open‑market purchase on Form 4. The filing shows a buy of 13,513 shares of common stock at $1.49 per share on 11/10/2025 (Transaction Code: P). Following the trade, the director beneficially owns 13,514 shares, held directly.